Map Home
Type / to search with text or keywords
/
keyboard shortcut: Type "/" on your keyboard for a quick search
Search button
Loading...
Loading...
Scroll left
Grants
Citations
H-Index
Patents
News
Books
Scroll right
Collapse sidebar
Data issues & feedback
Adjust height of sidebar
KMap
Department
Adjust height of sidebar
KMap
Department
Neurology
21 active people
179 grants
Recent Grants
Expanding AD Biomarkers in NIA funded PhytoSERM Efficacy to Prevent Menopause Associated Decline in Brain Metabolism and Cognition: A Double-Blind, Randomized, Placebo-Controlled Phase 2 Clinical Tria
2024
·
$1.8M
biomarkers,
menopause,
brain metabolism,
cognition,
clinical trial
Disrupted Lipid Metabolism in Alzheimer's Disease
2024
·
$1.6M
alzheimer's disease,
lipid metabolism,
brain health,
neurodegeneration,
metabolic disorders
Study to Evaluate Safety, Efficacy and Tolerability of ABBV-950 for the Treatment of Upper Limb Spasticity in Adult Post-Stroke Patients
2024
·
$822.1K
stroke rehabilitation,
spasticity treatment,
drug safety,
efficacy evaluation,
tolerability assessment
PNA5, an Angiotensin-(1-7) Glycopeptide, to Treat Dementia in Parkinson's Disease
2024
·
$518.6K
neuroscience,
pharmacology,
dementia,
parkinson's,
therapeutics
A Phase 2b, Multinational, Randomized, Double-blind Study to Investigate the Efficacy and Safety of Redasemtide (S-005151) Compared With Placebo in Adult Participants With Acute Ischemic Stroke Who Ar
2024
·
$470.3K
stroke,
clinical trial,
medication,
safety,
efficacy
A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study of the Safety and Neuroprotective Capacity of Scp776 in Subjects Undergoing Endovascular Thrombectomy for Acute Ischemic Stroke
2024
·
$422.6K
neuroprotection,
stroke,
clinical trial,
thrombectomy,
pharmacology
APOE Regulation of Neuron-Astrocyte Metabolic Coupling in Alzheimer's Disease
2024
·
$378.5K
alzheimer's disease,
metabolic coupling,
neuron-astrocyte interactions,
apoe regulation,
neurodegeneration
Protocol Title: A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Multiple Doses of LT3001 Drug Product in Subjects with Acute Ischemic Stroke (AIS)
2024
·
$370.5K
stroke,
drug efficacy,
safety evaluation,
clinical trial,
ischemic stroke
A Multi-Center, Phase IIA, Randomized, Double-Blind, Prospective, Active Placebo- Controlled Trial of Sub-Anesthetic Intravenous Infusion of Ketamine to Treat Levodopa- Induced Dyskinesia in Subjects
2024
·
$303.6K
ketamine,
dyskinesia,
levodopa,
clinical trial,
anesthetic infusion
Infection and Inflammation as Drivers of Aging (IIDA) Predoctoral Training Program
2024
·
$292.3K
aging,
infection,
inflammation,
pre-doctoral,
training
Diversity in Research Education in Aging Medicine and Science
2024
·
$288.3K
diversity,
education research,
aging,
medicine,
science
A Phase 2, multicenter, Open-Label, Long-Term Safety Study of LP352 in Subjects with Developmental and Epileptic Encephalopathy who Completed Study LP352-201 and are Candidates for Continuous Treatmen
2024
·
$19.8K
epileptic encephalopathy,
long-term safety,
developmental disorders,
continuous treatment
A Treatment for Neuropsychological and Memory Impairments Following Moderate to Severe Traumatic Brain Injury
2023
·
$3M
neuropsychology,
memory impairments,
traumatic brain injury,
treatment,
cognitive rehabilitation
PNA5: A Novel Mas Receptor Agonist for Treatment of Cognitive Impairment in Patients at Risk for Vascular Dementia and Alzheimer's Disease Related Dementia: An FDA Required Toxicology
2023
·
$2.2M
cognitive impairment,
vascular dementia,
alzheimer's disease,
mas receptor agonist,
toxicology
A First-in-human (FIH) Study of Inhibitory Interneurons (NRTX-1001) in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (MTLE)
2023
·
$749.8K
neuroscience,
epilepsy,
clinical trial,
drug resistance,
inhibitory interneurons
Phase 1/2a Dose Escalation Study of ANPD001 in Sporadic Parkinson Disease
2023
·
$597.6K
parkinson's disease,
dose escalation,
clinical trial,
neurodegenerative diseases
A Phase 1b/2a Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy
2023
·
$543.6K
clinical trials,
pharmacology,
safety,
efficacy,
dose escalation
Identifying Human Neuron IFN-y Dependent Anti-Toxoplasma Gondii Responses
2023
·
$422.1K
neurobiology,
immunology,
infectious disease,
cell biology,
neuroimmunology
A Multicenter, Randomized, Placebo Controlled, Double-blind, Parallel Group and Event Driven Phase 3 Study of the Oral Fxla Inhibitor Asundexian (Bay 2433334) for the Secondary Prevention of Ischemic
2023
·
$399.7K
clinical trials,
cardiovascular disease,
pharmacology,
ischemic events,
drug development
A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor Xla Inhibitor, for Stroke Prevention After an Acute Is
2023
·
$341.3K
stroke prevention,
factor xa inhibitor,
efficacy and safety,
acute ischemic stroke
People
Anita Koshy
Professor
Bruce Coull
Vice Dean
Ealaf Al rabia
Associate Clinical Professor, Neurology - (Clinical Series Track)
Firas Kaddouh
Assistant Clinical Professor, Neurology - (Clinical Series Track)
Francesca Vitali
Assistant Research Professor
Gerson Hernandez
Senior Director
Alex Hishaw
Associate Professor
Holli Horak
Professor
Katalin Scherer
Professor
David Labiner
Department Head
Hong Lei
Professor, Neurology - (Clinical Scholar Track)
Linda Restifo
Professor
Lalitha Madhavan
Associate Professor
Mandi Corenblum
Research Technologist II
Myrka Torres
Associate Clinical Professor, Neurology - (Clinical Series Track)
Adriana O'Dell
Medical Education Program Professional I
Rui Chang
Associate Professor
Sudeshna Bose
Clinical Associate Professor, (Clinical Series Track)
Scott Sherman
Professor
Vijayan Ramachandran
Scientific Analyst II
Kuixi Zhu
Research Specialist, Principal
